Arcturus TherapeuticsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Arcturus Therapeutics (ARCT) reported revenue of $3.00M in Q2 2026, with Grant its largest revenue segment at 70%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
Arcturus TherapeuticsSelf-amplifying mRNA. Kostaive COVID vaccine commercial in Japan with partners. Small-cap platform peer, not a US seasonal franchise.
Arcturus Therapeutics (ARCT) is a Biotechnology company. Self-amplifying mRNA. Kostaive COVID vaccine commercial in Japan with partners. Small-cap platform peer, not a US seasonal franchise. It was founded in 2013, is headquartered in San Diego, CA and employs about 200 people.
As of 2026-Q2, Arcturus Therapeutics's revenue breaks down across Grant (70%), Collaboration Revenue (30%). See the revenue-by-segment chart for the full mix.
Track Arcturus Therapeutics's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Arcturus Therapeutics in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching Arcturus Therapeutics, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.